James Liu is a U.S. market entry, CFIUS review, and cross-border M&A lawyer based in New York, practicing at Phillips Nizer LLP. With about 18 years of experience, James advises Chinese companies and investors that need practical outbound counsel outside Mainland China.

Practice Focus

• ⚖️ Core work: U.S. market entry, CFIUS review, and cross-border M&A
• 🌏 Clients: Chinese outbound groups, founders, and investment vehicles
• 📍 Base: New York
• 🗣️ Languages: English and Mandarin Chinese

He is engaged when generic templates or pure Chinese-law assumptions would create avoidable exposure in New York.

Credentials

How Engagements Typically Run

Diagnostic first

He starts with parties, timeline, documents already signed, cash moved, and regulatory touchpoints. Then he proposes a phased plan with decision gates so Chinese headquarters can authorize work in controlled increments.

Process discipline

• 📜 Align bilingual versions of operative documents
• 🛡️ Preserve privilege and evidence integrity where available
• 💼 Sequence filings to commercial milestones
• 📋 Document assumptions for HQ and overseas teams

Clear options beat abstract lectures. Liu translates local procedure into decisions Chinese executives can act on.

Problems Chinese Outbound Clients Often Face

Industry coverage spans technology, manufacturing, trading, real estate, and holding structures depending on the file. His value is reducing uncertainty under time pressure—not theatrical advocacy for its own sake.

Working Style

• 🧭 Direct recommendations with trade-offs stated plainly
• 🤝 Coordinates with tax, finance, and technical teams so advice is implementable
• 📚 Monitors regulatory updates relevant to Chinese outbound activity in New York
• 🔐 No published phone/email/WeChat — contact via the site form only

Professional Standards

James Liu does not promise outcomes, guaranteed approvals, or guaranteed awards. Advice is informational and strategic, grounded in the facts presented and the law of the relevant jurisdiction. Sensitive information is handled under professional confidentiality norms of the practice location.

Beyond Single Matters

He also helps Chinese clients build repeatable playbooks: clause libraries, escalation matrices, document retention habits, and counterparty onboarding standards. These operational tools often prevent the next dispute more effectively than any single contested hearing.

Looking forward, his practice remains centered on Chinese-client outbound needs in New York. Whether the file is preventive counseling or active controversy, the objective is controlled process and commercially usable advice.

Practice Philosophy

James Liu believes that successful US market entry for Chinese companies depends on getting the foundation right before making significant commitments. He emphasizes upfront regulatory risk assessment, entity structure planning, and compliance infrastructure as prerequisites to commercial activity. His approach prioritizes practical solutions that work within the realities of Chinese capital controls, approval processes, and corporate decision-making hierarchies.

Typical Engagement Workflow

James follows a phased engagement model tailored to the Chinese corporate environment. Phase one conducts a regulatory landscape review identifying all applicable US federal and state requirements, CFIUS exposure, and sector-specific licensing needs. Phase two develops an entity structure and market entry roadmap with clear timelines and cost estimates. Phase three implements the structure through entity formation, regulatory filings, and compliance program establishment. Post-launch monitoring ensures ongoing compliance obligations are met.

• 📋 Phase 1: US regulatory landscape assessment and CFIUS pre-screen
• 📜 Phase 2: Market entry structure design with capital flow planning
• ⚖️ Phase 3: Entity formation, licensing, and compliance implementation
• 🛡️ Phase 4: Ongoing compliance monitoring and reporting

Client Industries Served

James advises Chinese companies across technology, life sciences, and advanced manufacturing sectors. His technology clients include software companies establishing US operations, e-commerce platforms entering the North American market, and artificial intelligence companies navigating US technology export controls. Life sciences clients include pharmaceutical and medical device companies seeking FDA approval pathways and clinical trial partnerships. Manufacturing clients include automotive parts suppliers and electronics manufacturers establishing US production facilities.

Regulatory Monitoring Approach

James maintains a structured regulatory monitoring program tracking CFIUS developments, US export control amendments, sanctions designations, and sector-specific regulatory changes affecting Chinese inbound investment. He follows Treasury CFIUS guidance, Commerce BIS rulemakings, and OFAC sanctions updates. Alerts are generated for clients whose business activities are affected by regulatory changes, with practical recommendations for adjustment.

Cross-Border Coordination Patterns

US-China cross-border transactions require coordination between US counsel, Chinese law firms handling PRC regulatory approvals, and often Hong Kong counsel for intermediate holding structures. James establishes a coordination framework with defined roles, responsibilities, and communication protocols at the engagement outset. Weekly status calls during active transactions and monthly check-ins during ongoing compliance periods maintain alignment across the legal team and with client business stakeholders.

James structures CFIUS readiness assessments that match US regulatory timelines with Chinese corporate approval cycles.

For Chinese buyers, James recommends engaging local US counsel during the preliminary screening phase rather than after signing, when CFIUS timeline pressure may force less favorable outcomes.